| | | | | |
Drastic Action Needed Over Diabetes Explosion Tue, 04 Jun, 2013 04:56 PM PDT Drastic action including an assault on fatty fast foods and sweet drinks is needed to fight the looming diabetes epidemic says New Zealand First Health spokesperson Barbara Stewart. This follows the release of research that reveals more than 20 per ... Continue reading | | No diabetes drugs at Malawi's Queen Elizabeth Central hospital Tue, 04 Jun, 2013 04:55 PM PDT Some patients, who are battling with Blood Pressure or diabetes and receive drugs at Queen Elizabeth Central Hospital in Blantyre, have expressed worry over continued unavailability of drugs for such incommunicable diseases at the facility's pharmacy. They are particularly in fear of increased risk of ... Continue reading | | |
| | The Doctors: Should you get genetic testing? Tue, 04 Jun, 2013 04:35 PM PDT There's no simple yes or no to this one: Genetic testing helps show if you're at risk for developing diseases such as colon cancer, type 2 diabetes or Huntington's disease. It can give a glimpse into your future. Continue reading | | Obesity surgery-diabetes study shows pros and cons Tue, 04 Jun, 2013 04:10 PM PDT CHICAGO (AP) - Obesity surgery worked much better at reducing and even reversing diabetes than medication and lifestyle changes in one of the most rigorous studies of its kind. But the researchers and others warn that possible serious complications need to be considered. Continue reading | |
Press Release Tue, 04 Jun, 2013 04:09 PM PDT NeuroMetrix Inc. Posted on:05 Jun 13 NeuroMetrix Inc. (Nasdaq:NURO) (the "Company" or "NURO") a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes today announced that it entered into a definitive securities purchase agreement with a single insti... Continue reading | | | NeuroMetrix Announces $5 Million Preferred Stock Placement Tue, 04 Jun, 2013 03:08 PM PDT WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that it entered into a definitive securities purchase agreement with a single instit... Continue reading | |
No comments:
Post a Comment